iCAD, Inc. (NASDAQ:ICAD) Short Interest Up 20.1% in March

by · The Cerbat Gem

iCAD, Inc. (NASDAQ:ICAD – Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 269,400 shares, an increase of 20.1% from the March 15th total of 224,300 shares. Based on an average daily trading volume, of 459,200 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.0% of the shares of the stock are short sold.

iCAD Trading Down 5.9 %

iCAD stock traded down $0.19 during mid-day trading on Monday, reaching $3.03. The company had a trading volume of 817,471 shares, compared to its average volume of 358,070. The business has a fifty day simple moving average of $2.35 and a 200 day simple moving average of $2.14. The company has a market cap of $82.92 million, a P/E ratio of -23.31 and a beta of 1.78. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $3.78.

iCAD (NASDAQ:ICAD – Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The technology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.02. The company had revenue of $5.41 million for the quarter, compared to the consensus estimate of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.

Institutional Investors Weigh In On iCAD

Several hedge funds have recently added to or reduced their stakes in ICAD. Perritt Capital Management Inc lifted its holdings in shares of iCAD by 1.9% during the fourth quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company’s stock worth $346,000 after purchasing an additional 3,600 shares during the period. waypoint wealth counsel grew its position in shares of iCAD by 44.0% in the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after buying an additional 4,400 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock valued at $72,000 after buying an additional 13,402 shares during the last quarter. Thompson Davis & CO. Inc. acquired a new stake in shares of iCAD in the fourth quarter valued at about $31,000. Finally, Geode Capital Management LLC raised its position in shares of iCAD by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company’s stock worth $506,000 after acquiring an additional 17,059 shares during the last quarter. 24.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ICAD shares. Laidlaw reiterated a “hold” rating on shares of iCAD in a research report on Thursday. BTIG Research cut iCAD from a “buy” rating to a “neutral” rating in a report on Wednesday. Finally, StockNews.com lowered iCAD from a “hold” rating to a “sell” rating in a research note on Thursday.

Read Our Latest Stock Analysis on iCAD

iCAD Company Profile

(Get Free Report)

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.

Read More